top of page

No-Exam Term Life Insurance with Coronary Artery Disease or Stents: Instant Lane vs Full Underwriting

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Coronary artery disease, stents, and bypass history usually trigger a deeper review because underwriting wants to understand the event timeline and current stability, not just the diagnosis name.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

CAD/Stents: Timing and Stability Matter

Time since stent, bypass, MI, or hospitalization

Current symptoms, medications, and risk factor control

Cardiology follow-up and recent testing results

Coronary artery disease underwriting is not a binary insurable-or-not question - it is a severity and stability analysis that requires more information than any accelerated program can gather quickly. One of the first factors underwriters examine is the extent of vessel involvement: single-vessel disease treated with one stent carries a different risk profile than two-vessel disease, and three-vessel disease or left main coronary artery disease that required bypass surgery (CABG) represents a significantly higher level of anatomical involvement. The number of vessels affected, the location of the blockages, and whether the revascularization was complete - meaning all significant blockages were treated - all factor into the underwriting assessment before a rate class is assigned.

Ejection fraction (EF), measured by echocardiography, is one of the most important objective metrics in post-cardiac-event underwriting. EF measures the percentage of blood the left ventricle ejects with each contraction, and a normal EF at or above 55 percent after a cardiac event signals that the heart muscle preserved its pumping function - a favorable finding underwriters weigh heavily. A reduced EF below 40 percent indicates myocardial damage significant enough to impair left ventricular function, which triggers meaningfully different underwriting treatment and is associated with higher long-term mortality risk. EF values between 40 and 54 percent fall in an intermediate range that carriers evaluate alongside other clinical factors such as symptom burden, stress test findings, and current medication regimen.

Post-stent medication adherence is an underwriting data point because the standard protocol following percutaneous coronary intervention (PCI) involves dual antiplatelet therapy - typically aspirin combined with a P2Y12 inhibitor such as clopidogrel or ticagrelor - along with a statin and often a beta-blocker to reduce in-stent thrombosis risk and manage residual cardiovascular risk factors. Carriers may ask whether the applicant is currently on these medications and adherent to the protocol, because deviation from guideline-directed medical therapy after a stent is associated with elevated event recurrence risk. Documented adherence through prescription fill history is a favorable signal, and because carriers can verify fill history through database checks, a protocol medication that appears in pharmacy records but is listed as discontinued on the application creates a discrepancy that underwriters will flag for clarification. Resolving those discrepancies before submitting the application - with an accurate current medication list - prevents delays after the case is in underwriting.

Stress testing performed after coronary intervention provides objective evidence of whether revascularization achieved adequate blood flow restoration to the heart muscle. A normal nuclear perfusion study or stress echocardiogram at six to twelve months post-stent - showing no inducible ischemia, meaning no areas of the heart that become oxygen-deprived under stress - is one of the most favorable documents an applicant can provide in a CAD underwriting package. It demonstrates that the treated vessels are functioning, that the surrounding myocardium is perfused, and that the intervention achieved its clinical objective. Carriers who might otherwise rate the case may apply a lower table rating or consider a closer-to-standard offer when a normal post-intervention stress test is on file.

The timeline from the most recent cardiac event to the application date is a primary underwriting variable that changes which carriers will consider the case and at what rates. A stent placed in the past six to twelve months may result in postponement at most carriers while the stabilization period completes; the same case at three to five years post-procedure with normal follow-up testing and no new events may be approvable at a substandard rate class or, in the best presentations, closer to standard. Using accurate dates in the application is not a technicality - a difference of one year in the timeline can change the number of carriers willing to offer, the available rate class, and the face amount accessible without additional documentation.

For the broader no-exam term life overview and underwriting basics, see: https://www.careproinsurance.com/instant-term-life-insurance

This is informational material; professional advice on legal, tax, or medical matters should come from qualified sources. What you see at the quote stage reflects general pricing before underwriting adjustments.

Frequently Asked Questions

Can I get no-exam term life insurance with coronary artery disease?

Sometimes, but many instant/accelerated programs are restrictive with CAD and stent/bypass history. Options depend on timing, stability, and underwriting guidelines.

Why do instant programs exclude CAD or stents?

Because CAD histories often require timeline and testing review. Accelerated programs use strict filters and may not be able to evaluate those details quickly.

Does time since a stent affect underwriting?

Yes. Recency and stability since the procedure are commonly important factors. Exact lookback windows and requirements vary by carrier.

What CAD details should I have ready before applying?

Helpful details include event dates, procedure type (stent/bypass), current meds, symptoms, and recent cardiology follow-up/testing. Requirements vary.

Will I need a medical exam with CAD history?

Not always, but more documentation is common. Requirements depend on the carrier, coverage amount, and specifics of your history.

What is the difference between PCI and CABG in underwriting terms?

PCI (percutaneous coronary intervention) refers to catheter-based procedures including balloon angioplasty and stent placement, which open blocked arteries without open-heart surgery. CABG (coronary artery bypass grafting) is open-heart surgery that creates new blood flow routes around blocked segments using vessel grafts. Underwriters view these differently because CABG is typically reserved for more extensive or complex disease - multi-vessel or left main involvement - which carries different long-term risk implications than single-vessel stenting.

What is in-stent restenosis and does it affect underwriting?

In-stent restenosis is the re-narrowing of a coronary artery at the site of a previously placed stent, typically due to neointimal tissue growth within the stent. A history of restenosis requiring repeat intervention is a more adverse underwriting signal than a single uncomplicated stent, because it indicates that the initial revascularization did not produce durable results. Carriers will ask about any repeat procedures and may apply a higher table rating or a longer waiting period before offering coverage.

Do cardiac risk factors like high blood pressure or diabetes affect term life underwriting separately from the CAD history?

Yes. Underwriters evaluate control of underlying cardiovascular risk factors as part of the overall CAD assessment. Uncontrolled hypertension, poorly managed diabetes (reflected in elevated HbA1c), or untreated hyperlipidemia alongside a CAD history creates compounding risk that affects the rate class offered. Well-controlled comorbidities with documented medication adherence is a more favorable picture than CAD with unmanaged contributing conditions.

Get Covered With The Right Plan

Explain why CAD, stents, or bypass history usually doesn't fit instant approval, and what underwriters evaluate around stability, timing, and follow-up testing.

Compare term life options

bottom of page